EP0937095A4 - Targeted cytolysis of cancer cells - Google Patents
Targeted cytolysis of cancer cellsInfo
- Publication number
- EP0937095A4 EP0937095A4 EP97911757A EP97911757A EP0937095A4 EP 0937095 A4 EP0937095 A4 EP 0937095A4 EP 97911757 A EP97911757 A EP 97911757A EP 97911757 A EP97911757 A EP 97911757A EP 0937095 A4 EP0937095 A4 EP 0937095A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer cells
- cytolysis
- targeted
- targeted cytolysis
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2902996P | 1996-10-25 | 1996-10-25 | |
US29029P | 1996-10-25 | ||
PCT/US1997/018707 WO1998018809A1 (en) | 1996-10-25 | 1997-10-24 | Targeted cytolysis of cancer cells |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0937095A1 EP0937095A1 (en) | 1999-08-25 |
EP0937095A4 true EP0937095A4 (en) | 1999-12-22 |
Family
ID=21846848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97911757A Withdrawn EP0937095A4 (en) | 1996-10-25 | 1997-10-24 | Targeted cytolysis of cancer cells |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0937095A4 (en) |
JP (1) | JP2002512502A (en) |
AU (1) | AU744160B2 (en) |
CA (1) | CA2269738A1 (en) |
WO (1) | WO1998018809A1 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
KR20020073127A (en) * | 1999-09-17 | 2002-09-19 | 겐자임 트랜스제닉스 코포레이션 | Transgenically produced fusion proteins |
US7569673B2 (en) | 2002-06-28 | 2009-08-04 | The United States Of America As Represented By The Department Of Health And Human Services | Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors |
US7589181B2 (en) | 2003-08-29 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
KR20120117931A (en) * | 2010-02-12 | 2012-10-24 | 온코메드 파마슈티칼스, 인크. | Methods for identifying and isolating cells expressing a polypeptide |
KR102062407B1 (en) | 2010-12-09 | 2020-01-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Use of chimeric antigen receptor-modified t cells to treat cancer |
US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
EP3505537A1 (en) | 2012-05-07 | 2019-07-03 | Trustees of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
PT2958943T (en) | 2013-02-20 | 2019-12-17 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
TWI654206B (en) | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
AU2014296059B2 (en) * | 2013-08-02 | 2020-12-10 | The Regents Of The University Of California | Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors |
CA3225453A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
JP6793902B2 (en) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | Adjustable chimeric antigen receptor |
EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
IL293603B2 (en) | 2014-04-07 | 2024-03-01 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
CN106687483B (en) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptors |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
CN112481283A (en) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | Treatment of cancer using CD33 chimeric antigen receptor |
MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
DK3194443T3 (en) | 2014-09-17 | 2021-09-27 | Novartis Ag | TARGETING OF CYTOTOXIC CELLS WITH CHIMARY RECEPTORS IN CONNECTION WITH ADOPTIVE IMMUNTERAPHY |
SG11201702895SA (en) | 2014-10-08 | 2017-05-30 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
KR20170093254A (en) | 2014-12-29 | 2017-08-14 | 노파르티스 아게 | Methods for producing chimeric antigen receptor-expressing cells |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
SI3280729T1 (en) | 2015-04-08 | 2022-09-30 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
JP7114457B2 (en) | 2015-04-17 | 2022-08-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells |
AR105433A1 (en) | 2015-07-21 | 2017-10-04 | Novartis Ag | METHODS TO IMPROVE THE EFFECTIVENESS AND EXPANSION OF IMMUNE CELLS |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
JP6905163B2 (en) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Biomarkers that predict cytokine release syndrome |
AU2016361451B2 (en) | 2015-11-27 | 2024-01-25 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
JP7082055B2 (en) | 2015-12-22 | 2022-06-07 | ノバルティス アーゲー | Antibodies to Mesothelin Chimeric Antigen Receptor (CAR) and PD-L1 Inhibitors for Combined Use in Anticancer Treatment |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
AR110676A1 (en) | 2016-10-07 | 2019-04-24 | Novartis Ag | TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
KR20190130608A (en) | 2017-03-22 | 2019-11-22 | 노파르티스 아게 | Compositions and Methods for Immune Oncology |
AU2019225393A1 (en) * | 2018-02-23 | 2020-08-20 | Cartherics Pty. Ltd. | T cell disease treatment targeting TAG-72 |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5359046A (en) * | 1990-12-14 | 1994-10-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103521A (en) * | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
-
1997
- 1997-10-24 EP EP97911757A patent/EP0937095A4/en not_active Withdrawn
- 1997-10-24 CA CA002269738A patent/CA2269738A1/en not_active Abandoned
- 1997-10-24 AU AU49058/97A patent/AU744160B2/en not_active Ceased
- 1997-10-24 WO PCT/US1997/018707 patent/WO1998018809A1/en not_active Application Discontinuation
- 1997-10-24 JP JP52053098A patent/JP2002512502A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5359046A (en) * | 1990-12-14 | 1994-10-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
Non-Patent Citations (8)
Title |
---|
ESHHAR ET AL: "SPECIFIC ACTIVATION AND TARGETING OF CYTOTOXIC LYMPHOCYTES THROUGH CHIMERIC SINGLE CHAINS CONSISTING OF ANTIBODY-BINDING DOMAINS AND THE GAMMA OR ZETA SUBUNITS OF THE IMMUNOGLOBULIN AND T-CELL RECEPTORS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, 1 January 1993 (1993-01-01), pages 720 - 724, XP002088319 * |
HOMBACH A ET AL: "T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope.", GASTROENTEROLOGY, (1997 OCT) 113 (4) 1163-70. JOURNAL CODE: FH3. ISSN: 0016-5085., United States, XP002117237 * |
HOMBACH, A. ET AL: "Expression of functional active chimeric T-cell receptors with antibody like specificity for the TAG72 tumor antigen.", ANNALS OF HEMATOLOGY, (1996) VOL. 73, NO. SUPPL. 2, PP. A152. MEETING INFO.: ANNUAL CONGRESS OF THE GERMAN AND THE AUSTRIAN SOCIETY OF HEMATOLOGY AND ONCOLOGY DUESSELDORF, GERMANY OCTOBER 3-7, 1996 ISSN: 0939-5555., XP002117385 * |
MCARTHUR, J. G. (1) ET AL: "Targeting of tumor cells by T cells transduced with TAG-72 tumor antigen specific MHC-unrestricted chimeric T cell receptors.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (1997) VOL. 38, NO. 0, PP. 37. MEETING INFO.: EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH SAN DIEGO, CALIFORNIA, USA APRIL 12-16, 1997 ISSN:, XP002117386 * |
MCGUINNESS R P ET AL: "Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor [see comments].", HUMAN GENE THERAPY, (1999 JAN 20) 10 (2) 165-73. JOURNAL CODE: A12. ISSN: 1043-0342., United States, XP002117239 * |
MCGUINNESS, R. ET AL: "Targeting of tumor cells by T lymphocytes expressing tumor associated antigen specific, MHC-unrestricted chimeric T cell receptors.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (1997) VOL. 99, NO. 1 PART 2, PP. S41. MEETING INFO.: JOINT MEETING OF THE AM. ACAD. OF ALLERGY, ASTHMA AND IMMUNOL., THE AM. ASSOC. OF IMMUNOL. AND THE CLIN. IMMUNOL. SOC. SAN FRANSCISCO, FEBR. 21-26, 1997, XP002117387 * |
SCHLOM, J. ET AL.: "Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates", CANCER RESEARCH, vol. 52, 1 March 1992 (1992-03-01), pages 1067 - 1072, XP002117238 * |
See also references of WO9818809A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU744160B2 (en) | 2002-02-14 |
CA2269738A1 (en) | 1998-05-07 |
JP2002512502A (en) | 2002-04-23 |
AU4905897A (en) | 1998-05-22 |
EP0937095A1 (en) | 1999-08-25 |
WO1998018809A1 (en) | 1998-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0937095A4 (en) | Targeted cytolysis of cancer cells | |
GB9622500D0 (en) | Therapeutic gene | |
ZA972494B (en) | Long wearing lipstick | |
EP0934404A4 (en) | Inhibition of proliferation of cells | |
HU9702242D0 (en) | Inozitol-glykanes of inzulin-like activity | |
EP0972830A4 (en) | Cancer-associated genes | |
AU6537798A (en) | Targeted cytolysis of cancer cells | |
EP0804550A4 (en) | Ex vivo activation of immune cells | |
GB9602704D0 (en) | Structure of perculator | |
GB9605453D0 (en) | Cultured cells | |
GB9617184D0 (en) | Enzyme | |
IL129474A0 (en) | Targeted cytotoxic cells | |
PL328829A1 (en) | Enzyme | |
PL313849A1 (en) | Beta-aminoesters of o-hydrobenzylamides | |
GB2333527B (en) | Therapeutic gene | |
TW312301U (en) | Improved structure of earmask | |
TW319017U (en) | Improved structure of mousetraps | |
GB9713139D0 (en) | Use of enzymes | |
GB9621289D0 (en) | Pond | |
GB9617709D0 (en) | Enzyme | |
GB9723412D0 (en) | Cancer gene | |
TW309212U (en) | Runner system of fuel cell | |
TW304520U (en) | Improved structure of groyne | |
AP9600848A0 (en) | Ther peuti amid s | |
TW301421U (en) | Improved structure of rotaion-type calculator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990422 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19991104 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20020910 |